Why is Cohance Life falling/rising?

As of 22-Sep, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 901.75, which reflects a decrease of Rs 7.7 or 0.85%. The stock has been underperforming, having fallen for the last four consecutive days, resulting in an overall return of -8.88% during this period. It is also trading close to its 52-week low, just 4.97% above that level. The stock's performance over the past year shows a significant decline of -26.15%, which is notably worse than the broader market's decline of -2.82%. Additionally, the company's financial health is concerning, with a low operating profit growth rate of 2.95% over the last five years and a substantial drop in profit after tax by -41.1% compared to the previous four-quarter average. The high level of pledged promoter shares, which has doubled in the last quarter, adds further pressure on the stock price.
In the broader market context, the stock's short-term performance has been significantly worse than the benchmark, with a one-week return of -8.39% compared to a slight gain of +0.46% in the Sensex. This stark contrast highlights the stock's struggles relative to the overall market. Despite a high management efficiency indicated by a return on equity of 24.14% and a low debt-to-equity ratio, the stock's valuation remains expensive compared to its peers, which may deter investors. The falling investor participation, evidenced by a dramatic drop in delivery volume, further suggests a lack of confidence in the stock's future performance, contributing to its current downward trend.